ClinicalTrials.gg
Active, not recruitingNCT04302025NAUTIKA1Updated Nov 10, 2026

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Alectinib and Entrectinib in Non-small Cell Lung Cancer, sponsored by Genentech, Inc.. Active, not recruiting at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

Updated Nov 10, 2026Now Active, not recruiting14 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung — 7 open to participants now, 14 under way, 4 of them phase 3. alectinib · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
13th of 27
99 · median 90
Started
2020
with 1 other
Phase 2
9 of 27
4 open now
Primary completion
2026-11
later than 4 of 13 live
Registered
16th of 27
by date
Lead sponsor
1 of 27
Genentech, Inc.

Among the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by planned enrollment, is one of 2 that started in 2020, is one of 9 in phase 2, reaches primary completion later than 4 of the 13 other live ones, and was the 16th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About alectinib

alectinib: first FDA approval 2015 (ALECENSA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing alectinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

03

Conditions studied

  • Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented NSCLC:
  • Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) NSCLC staging system
  • T4 primary NSCLC will be allowed only on the basis of size. Invasion of the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodules in a different ipsilateral lobe is not permitted
  • All participants will undergo clinical staging using computed tomography (CT) and positron emission tomography (PET) scanning, as well as brain imaging using magnetic resonance imaging (MRI). Invasive mediastinal staging by either mediastinoscopy or endo-bronchial ultrasonography is highly encouraged for participants with radiographically suspected mediastinal nodal disease (i.e., N2) but not mandated if the CT or PET scans showed no evidence of N2 disease
  • Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories and showing at least one of the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600 mutation, RET fusion, expression in ≥ 1% tumor cells as determined by Food and Drug Administration (FDA)-approved test, KRAS G12C mutation
  • , as defined by v1.1
  • NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground glass opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured based on the solid component only, exclusive of the ground glass opacity component
  • Evaluated by the attending surgeon prior to study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and verify that the participant is medically operable
  • Adequate pulmonary function to be eligible for surgical resection with curative intent
  • Adequate cardiac function to be eligible for surgical resection with curative intent
  • (ECOG) Performance Status of 0 or 1
  • Adequate hematologic and end-organ function
  • Negative surface antigen (HBsAg) test at screening for cohort
  • Negative total hepatitits B core antibody (HBcAb) test at screening for cohort, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) deoxyribonucleic acid (DNA) test at screening
  • Negative virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening
  • Male participants must be willing to use acceptable methods of
  • Female participants of must agree to use acceptable methods of contraception

Inclusion Criteria for Therapy (TKI Cohorts and KRAS G12C cohort [if continuing on Divarasib]):

  • Participants whose tumors lack radiographic progression
  • ECOG Performance Status of 0 or 1
  • Adequate hematologic and end-organ function

Exclusion criteria

Exclusion Criteria

  • NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
  • Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years
  • Participants with prior lung cancer
  • Major surgical procedure within 28 days prior to Cycle 1, Day 1
  • other than the disease under study within 3 years prior to Cycle 1, Day 1, with the exception of participants with a negligible risk of or death and with expected curative outcome
  • Treatment with an agent for any condition within 4 weeks prior to Cycle 1, Day 1
  • Participants known to be positive for (HIV) are excluded if they meet any of the following criteria: cluster of differentiation 4 (CD4)+ T-cell count of \<350 cells/microliters (cells/µL); detectable HIV viral load; history of an opportunistic infection within the past 12 months; on stable antiretroviral therapy for \<4 weeks
  • Severe infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact participant safety
  • Pregnant or lactating, or intending to become pregnant during the study
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    ALK Cohort (Enrolment Closed)

    Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care (SOC). All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib. Enrolment Closed.

    Drug: Alectinib · Procedure: Resection · Drug: Chemotherapy

  • Experimental
    ROS 1 Cohort (Enrolment Closed)

    Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed.

    Drug: Entrectinib · Procedure: Resection · Drug: Chemotherapy

  • Experimental
    NTRK Cohort (Enrolment Closed)

    Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed.

    Drug: Entrectinib · Procedure: Resection · Drug: Chemotherapy

  • Experimental
    BRAF Cohort (No Participants Enrolled, Cohort Closed)

    Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib. Cohort closed.

    Drug: Vemurafenib · Drug: Cobimetinib · Procedure: Resection · Drug: Chemotherapy

  • Experimental
    RET Cohort (Cohort closed)

    Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib. Cohort closed.

    Drug: Pralsetinib · Procedure: Resection · Drug: Chemotherapy

  • Experimental
    PD-L1 Cohort (Enrolment Closed)

    Participants with positive programmed death-ligand 1 (PD-L1) in ≥1% tumor cells will receive 4 cycles of atezolizumab neoadjuvant treatment. During neoadjuvant Cycle 1 of atezolizumab, participants will also receive low-dose stereotactic body radiation therapy (SBRT) (8 gray \[Gy\] X 3). Adjuvant treatment consists of SOC treatment as determined by the investigator, per National Comprehensive Cancer Network (NCCN) guidelines. Enrolment Closed.

    Drug: Atezolizumab · Drug: SBRT · Procedure: Resection

  • Experimental
    KRAS G12C Cohort

    Participants will receive up to 8 weeks of divarasib as neoadjuvant treatment before undergoing surgical resection per SOC. PD-L1 negative participants whose tumors have pathological response or lack radiographic progression will be have the option of continuing divarasib alone for up to 3 years or 1-4 cycles of SOC chemotherapy followed by divarasib for 3 years as adjuvant therapy. For participants who test positive PD-L1, they will have the option to receive 1-4 cycles of SOC chemotherapy followed by atezolizumab for up to 16 cycles or SOC alone.

    Procedure: Resection · Drug: Chemotherapy · Drug: Divarasib

Interventions

  • Participants will receive oral alectinib twice per day (BID).

    Also known as: CH5424802; RO5424802

  • Participants will receive oral entrectinib daily.

    Also known as: Rozlytrek®; RXDX-101

  • Participants will receive oral vemurafenib BID.

    Also known as: Zelboraf®

  • Participants will receive oral cobimetinib daily.

    Also known as: Cotellic®

  • Participants will receive oral pralsetinib daily.

    Also known as: Gavreto®

  • Atezolizumab will be administered by intravenous (IV) infusion.

    Also known as: Tecentriq®

  • DrugSBRT

    Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.

  • ProcedureResection

    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.

  • DrugChemotherapy

    Participants will receive SOC chemotherapy as determined by the treating physician.

  • Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.

    Also known as: GDC-6036

06

What researchers measure

Primary outcomes

  1. Tyrosine Kinase Inhibitor (TKI) Cohort: Proportion of Participants With Major Pathologic Response (MPR)

    MPR is defined as ≤ 10% residual viable tumor cells as scored by local pathologists.

    Time frame: After surgical resection (approximately study Week 8)

  2. Checkpoint Inhibitor (CPI) Cohort: Pathological Complete Response (pCR)

    Scored by local pathologists; defined as lack of any viable tumor cells on review of hematoxylin and eosin (H\&E) slides after complete evaluation of a resected lung cancer specimen including all sampled regional lymph nodes.

    Time frame: After surgical resection (approximately study Week 8)

  3. KRAS G12C Cohort: Percentage of Participants With 3-5 Grade Adverse Events (AEs)

    Time frame: After surgical resection (approximately study Week 8)

  4. KRAS G12C Cohort: Percentage of Participants Without Delays of Surgery due to Treatment-related AEs as Reported by the Investigator

    Time frame: After surgical resection (approximately study Week 8)

Secondary outcomes

  1. Proportion of Participants With MPR

    Defined as ≤10% residual viable tumor cells) based on surgical resection as defined by Hellmann et al. (2014) and Travis et al. (2020). TKI cohorts: MPR will be scored by a central pathology committee consensus read. CPI cohort: MPR will be scored by local pathologists and central pathology committee consensus read. KRAS G12C cohort: MPR will be scored by local pathologists and central pathology committee consensus read.

    Time frame: After surgical resection (approximately study Week 8)

  2. Proportion of Participants With pCR

    Defined as lack of any viable tumor cells on review of H\&E slides after complete evaluation of a resected lung cancer specimen, including all sampled regional lymph nodes. TKI cohorts: pCR will be scored by local pathologists and a central pathology committee consensus read. CPI cohort: pCR will be scored by a central pathology committee consensus read. KRAS G12C cohort: pCR will be scored by a central pathology committee consensus read.

    Time frame: After surgical resection (approximately study Week 8)

  3. Pathological Regression Based on Weighted % Viable Tumor Cell Assessment

    Time frame: After surgical resection (approximately study Week 8)

  4. Investigator-assessed Response Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)

    Time frame: After neoadjuvant treatment (after approximately study Week 8)

  5. Disease-free Survival (DFS)

    Time frame: From the first date of no disease to local or distant recurrence or death from any cause, whichever occurs first, through the end of the study (up to 9 years)

  6. Event-free Survival (EFS)

    Time frame: From first dose of study treatment to first documented disease progression per RECIST v1.1, or local or distant disease recurrence as determined by investigator, or death from any cause, whichever occurs first, through the end of study (up to 9 years)

  7. Overall Survival (OS)

    Time frame: From the first dose of study medication to death from any cause, through the end of the study (up to 9 years)

  8. Percentage of Participants With AEs

    Time frame: Up to 9 years

  9. Nodal Downstaging

    Defined as percentage of participants with reduced stages in regional lymph nodes at surgery.

    Time frame: After surgical resection (approximately study Week 8)

  10. Circulating tumor DNA (ctDNA) Clearance Rate

    Time frame: Prior to surgery (before study Week 8)

  11. KRAS G12C Cohort: Plasma Concentration of Divarasib at Specified Timepoints

    * Treatment completion/discontinuation; * Disease Progression or Recurrence during Neoadjuvant treatment or Surveillance; * Unscheduled (Tumor Evaluation and Response) \[Anytime up to 3 years\]

    Time frame: Neo-adjuvant: pre-dose & 2 hours post-dose on Day 1 of Cycles 1 & 2; Pre-surgery (before Week 8): pre-dose; Adjuvant treatment: pre-dose & 2 hours post-dose on Day 1 of Cycles 1-6, pre-dose on Day 1 of Cycle 9 (each cycle=28 days);

07

Study locations

24 sites
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Nov 2026, 72 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 72 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2020
First posted
Mar 10, 2020
StartActual
Nov 6, 2020
Primary completionEst.
Nov 30, 2026
CompletionEst.
May 30, 2030
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 10, 2026
Sites
14 sites removed
Show 14 removed
  • City of Hope Comprehensive Cancer Center · Duarte, United States
  • City of Hope - Orange County Lennar Foundation Cancer Center · Irvine, United States
  • USC Norris Cancer Center · Los Angeles, United States
  • Cedars-Sinai Medical Center · Los Angeles, United States
  • UCSF Helen Diller Family CCC · San Francisco, United States
  • University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) · Aurora, United States
  • Boston Medical Center · Boston, United States
  • Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center · Farmington Hills, United States
  • University Hospitals Cleveland Medical Center · Cleveland, United States
  • Tennessee Oncology - Nashville · Nashville, United States
  • Kelsey Seybold Clnic · Houston, United States
  • Baylor College of Medicine · Houston, United States
  • Lumi Research · Kingwood, United States
  • Seattle Cancer Care Alliance · Seattle, United States
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Recruiting→Active, not recruiting
    14 sites removed
    Show 14 removed
    • City of Hope Comprehensive Cancer Center · Duarte, United States
    • City of Hope - Orange County Lennar Foundation Cancer Center · Irvine, United States
    • USC Norris Cancer Center · Los Angeles, United States
    • Cedars-Sinai Medical Center · Los Angeles, United States
    • UCSF Helen Diller Family CCC · San Francisco, United States
    • University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center) · Aurora, United States
    • Boston Medical Center · Boston, United States
    • Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center · Farmington Hills, United States
    • University Hospitals Cleveland Medical Center · Cleveland, United States
    • Tennessee Oncology - Nashville · Nashville, United States
    • Kelsey Seybold Clnic · Houston, United States
    • Baylor College of Medicine · Houston, United States
    • Lumi Research · Kingwood, United States
    • Seattle Cancer Care Alliance · Seattle, United States
    + 2 other changes: verification date and contact details
  2. Oct 13, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04302025
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Mar 10, 2020
Start date
Nov 6, 2020
Primary completion
Nov 30, 2026 (estimated)
Completion
May 30, 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alectinib · Entrectinib · Vemurafenib · Cobimetinib · Pralsetinib · Atezolizumab · Divarasib

Start the discussion